- A Phase 2 trial of Oxigene's (OXGN) Zybrestat ovarian cancer drug (used in combination with Roche's Avastin) "met its primary endpoint of a statistically significant increase in progression-free survival." (PR)
- Oxigene expects full study results to be "submitted for presentation at a future scientific meeting."
- CEO Peter Langecker: "Zybrestat is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need."
at MarketWatch.com (Mar 12, 2014)